PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNYNF, SNY) reported positive results from a Phase 3 trial which evaluated Praluent (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline compared to 2 percent increase for placebo.
The companies reported that Praluent reduced the need for apheresis treatment by 75 percent compared to placebo, the primary endpoint of the study. Apheresis is a procedure similar to kidney dialysis where bad cholesterol is removed from the blood, and is usually reserved for high-risk patients with very high cholesterol.
Copyright RTT News/dpa-AFX